Association Between the Immunohistochemical GCB/non GCB Classification and the Outcome of the Patient With Diffuse Large B - Cell Lymphoma Treated With Rituximab - CHOP Regimen: Single Centre Experience

2013 ◽  
Vol 1 (1) ◽  
pp. 3
Author(s):  
S. Trajkova ◽  
L. Cevreska ◽  
A. Stojanovic ◽  
G. Petrusevska ◽  
D. Dukovski ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Single Centre ◽  
Chop Regimen ◽  
Large B Cell Lymphoma ◽  
Single Centre Experience ◽  
Large B Cell

scholarly journals Primary Diffuse large B-Cell lymphoma of testis: A single centre experience and review of literature

2014 ◽  
Vol 6 (3) ◽  
pp. 231 ◽  
Author(s):  
Vishwanath Sathyanarayanan ◽  
TM Suresh ◽  
Lokanatha Dasappa ◽  
Govinda BabuK Kanakasetty ◽  
CLakshmaiah Kuntegowdanahalli ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Review Of Literature ◽  
Single Centre ◽  
Large B Cell Lymphoma ◽  
Single Centre Experience ◽  
Large B Cell

scholarly journals Biology Reforms Treatment in Diffuse Large B Cell Lymphoma-Single Centre Experience

2018 ◽  
Vol 18 ◽  
pp. S269
Author(s):  
Sanja Trajkova ◽  
Gordana Petrusevska ◽  
Lidija Cevreska ◽  
Aleksandar Stojanovik ◽  
Marija Popova-Labachevska ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Single Centre ◽  
Large B Cell Lymphoma ◽  
Single Centre Experience ◽  
Large B Cell

scholarly journals Single Centre Retrospective Analysis: Transformation of Waldenström's Macroglobulinemia to Diffuse Large B-Cell Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 11-11
Author(s):  
Bert Heyrman ◽  
Nikki Granacher ◽  
Ka Lung Wu
Keyword(s):  
B Cell ◽  
Retrospective Analysis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Single Centre ◽  
The Past ◽  
Large B Cell Lymphoma ◽  
End Of Treatment ◽  
Large B Cell

Introduction: The incidence and outcome of Waldenström's macroglobulinemia (WM) patients with transformation to diffuse large B-cell lymphoma (DLBCL) are unclear. We performed a retrospective analysis to determine the incidence, clinicopathological characteristics and treatment outcome of WM patient with histologic transformation to DLBCL in our centre. Methods: Single centre chart review of WM patients in the past 10 years. Patients with histologic diagnosis of DLBCL after the diagnosis WM were included in our analysis. Results: Three of the 79 WM patients had histological transformation to DLBCL, two male and one female. Mean age at DLBCL development was 76,6 years. The mean time to transformation since diagnosis of WM was 8,3 years (14, 8 and 3 years). All three patients received at least one prior line of treatment in relation to WM (2, 1 and 3 prior lines). Different regimens used were cyclophosphamide/dexamethasone, rituximab/bendamustin, chlorambucil monotherapy, fludarabine monotherapy, R-CVP and ibrutinib monotherapy. The patients were in clinical CR from WM at the time of transformation, two patients were still on treatment. All three patients presented with advanced disease (stage IIIB, IVB, and IVA) non-GCB subtype DLBCL with at least 2 extra nodal sites. R-IPI scores were 4,5 and 4. Two patients were treated with R-miniCHOP, one patient received R-CHOP. The first patient achieved a CR at the end of treatment and is now 1,5 years in follow-up. The second patient died from pneumonia one year after achieving a CR. The third patient is in follow op since 3 months after reaching a CR at the end of treatment. Conclusion: Over the past decade transformation of WM to DLBCL was 3.7% in our centre. This is in accordance with previous data suggesting an 2.4% risk of transformation over 10 years.Time to transformation varies and no association with prior WM therapy and response to treatment can be found.All patients presented with more aggressive DLBCL in an advanced stage.All three patients achieved a CR following treatment for DLBCL, one patient died from pneumonia, two others are now in follow-up 1,5 years and 3 months respectively. Disclosures Heyrman: Celgene:Research Funding.

Primary anaplastic large B-cell lymphoma in mandible: Long-term complete remission with R-CHOP regimen and involved field radiotherapy

Oral Oncology ◽  
2009 ◽  
Vol 45 (9) ◽  
pp. e113
Author(s):  
Pasquale Niscola ◽  
Massimiliano Palombi ◽  
Malgorzata Monika Trawinska ◽  
Laura Scaramucci ◽  
Marco Giovannini ◽  
...  
Keyword(s):  
Complete Remission ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chop Regimen ◽  
Large B Cell Lymphoma ◽  
Involved Field ◽  
Involved Field Radiotherapy ◽  
Large B Cell

scholarly journals Primary Mediastinal Large B-Cell Lymphoma during Pregnancy

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Cesar A. Perez ◽  
Janki Amin ◽  
Luz M. Aguina ◽  
Maureen Cioffi-Lavina ◽  
Edgardo S. Santos
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intrauterine Pregnancy ◽  
Chop Regimen ◽  
Early Presentation ◽  
Large B Cell Lymphoma ◽  
Complex Scenario ◽  
Fdg Pet Ct ◽  
Large B Cell

Non-Hodgkin’s Lymphoma (NHL) rarely presents during pregnancy and primary mediastinal large B-cell lymphoma (PMLBCL) accounts for approximately 2.5% of patients with NHL. The case of a 22-year-old woman who was diagnosed with Stage IIA PMLBCL during week 13 of her intrauterine pregnancy is described. The staging consisted in computed tomography (CT) of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis. She was managed with R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for a total of six cycles and, because of the early presentation during the second trimester, she received the entire chemotherapy course during the pregnancy. She delivered a healthy baby at 34 weeks of pregnancy and a18FDG-PET/CT scan demonstrated complete remission after delivery. After 20 months of follow up she remains with no evidence of disease and her 1-year-old son has shown no developmental delays or physical abnormalities. PMLBCL, although an uncommon subgroup of DLBCL, may present during pregnancy and R-CHOP should be considered as one suitable option in this complex scenario.

Sign in / Sign up

Export Citation Format

Share Document